Welcome to our dedicated page for Microbot Med SEC filings (Ticker: MBOT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page compiles U.S. Securities and Exchange Commission (SEC) filings for Microbot Medical Inc. (NASDAQ: MBOT), a commercial stage medical device company focused on the LIBERTY Endovascular Robotic System. Through these filings, investors can review how the company reports material events, financing transactions, intellectual property developments and key commercialization steps for its endovascular robotics platform.
Microbot Medical uses current reports on Form 8-K to disclose significant milestones, including FDA 510(k) clearance for the LIBERTY System, the start of its limited market release in the U.S., and the first hospital adoption of LIBERTY for patient care at Emory University Hospital. Other 8-K filings describe partnerships with a U.S.-based third-party logistics provider to support commercialization, as well as the company’s exhibition of LIBERTY at major medical meetings.
Several 8-K filings also detail capital markets activity, such as the exercise of outstanding preferred investment options, issuance of new short-term preferred investment options and related gross proceeds. In these documents, Microbot Medical outlines intended uses of funds, including continued development, commercialization and regulatory activities for the LIBERTY Robotic System, potential acquisitions of complementary assets or products, expansion of applications derived from its IP portfolio, and working capital and general corporate purposes.
Additional filings address intellectual property events, such as the granting of the company’s first patent in Japan covering core LIBERTY System technology, and certain compensation decisions for executives and non-management directors. On Stock Titan, these filings are updated as they are made available through EDGAR, and AI-powered summaries can help explain the context and key points of each document, from material event disclosures to financing terms and governance changes related to MBOT.
Microbot Medical Inc. filed a report to share that it will participate in the virtual Oppenheimer 36th Annual Healthcare MedTech & Services Conference, held March 16–19, 2026. CEO, President and Chairman Harel Gadot will present live at 8:40 a.m. ET on March 19, 2026.
The company will highlight the expanding clinical experience and recent achievements from the limited market release of its LIBERTY Endovascular Robotic System. LIBERTY is described as the only FDA-cleared, single-use, remotely operated robotic system for peripheral endovascular procedures. Microbot began a limited market release in late 2025 and plans a full market release at the Society of Interventional Radiology conference in April 2026.
Microbot Medical Inc. filed a current report describing a press release about its LIBERTY® Endovascular Robotic System and recent policy from the American Medical Association on occupational radiation exposure. The AMA adopted a policy in late 2025 to strengthen protections for health care professionals and trainees exposed to ionizing radiation.
Microbot emphasizes that LIBERTY is remotely operated and, in the ACCESS-PVI Study, use of the system showed a 92% relative reduction in radiation exposure. The company began a Limited Market Release of LIBERTY in late 2025 and plans a Full Market Release at the Society of Interventional Radiology conference in April 2026.
Microbot Medical Inc. reported that its operations and commercial activities remain stable despite current geopolitical events in the Middle East. The company states there is no business disruption in either the U.S. or Israel, and that employee safety and security remain a top priority.
Following recent FDA clearance of its LIBERTY Endovascular Robotic System, Microbot is focusing commercialization on the U.S. market using a dedicated commercial team based in Hingham, Massachusetts. The company indicates internal operations and its lead manufacturing partner are fully functional, with sufficient U.S. inventory and additional stock being built through a third-party logistics partner.
Microbot is preparing for a full market release of the LIBERTY System at the Society of Interventional Radiology conference in April 2026, after beginning a limited market release in late 2025. To support expansion, it has hired additional U.S. sales representatives and a Director of Health Economics and Outcomes Research, while continuing to monitor Middle East developments to maintain uninterrupted customer support.
Microbot Medical Inc. reported changes to its executive employment arrangements and a one-time cash award. As of February 20, 2026, the company entered into an addendum to the employment agreement with Simon Sharon, an addendum with Rachel Vaknin, and an amendment to the employment agreement with Juan Diaz-Cartelle. On February 18, 2026, the board also authorized a special bonus of approximately $140,000 for CEO, President and Chairman Harel Gadot, which is in addition to bonuses he may receive under his existing employment agreement.
Microbot Medical reported that Tampa General Hospital has become the first health system in Florida to adopt its LIBERTY® Endovascular Robotic System, following recent FDA 510(k) clearance. The company sees this as early post-clearance momentum in a U.S. peripheral endovascular market of about 2.5 million procedures annually.
Microbot began a limited market release of LIBERTY in late 2025 and plans a full commercial launch at the Society of Interventional Radiology conference in April 2026. LIBERTY is described as a single-use, remotely operated robotic system designed to improve precision and reduce radiation exposure and physical strain during peripheral endovascular procedures.
Gadot Harel reported acquisition or exercise transactions in this Form 4 filing.
Microbot Medical Inc. reported that Chairman, President and CEO Harel Gadot received a grant of stock options covering 480,000 shares of common stock. These options were awarded under the company’s 2020 Omnibus Performance Award Plan.
According to the grant terms, 25% of the option vests and becomes exercisable on August 18, 2026. The remaining 75% vests and becomes exercisable in equal installments on a quarterly basis over the following 30 months, subject to the plan’s provisions on possible acceleration or forfeiture.
Diaz-Cartelle Juan reported acquisition or exercise transactions in this Form 4 filing.
Microbot Medical Inc. reported that Chief Medical Officer Juan Diaz-Cartelle received a grant of stock options covering 105,000 shares of common stock. These options were awarded at no cost as part of his compensation.
Under the company’s 2020 Omnibus Performance Award Plan, 25% of the options will vest and become exercisable on August 18, 2026. The remaining 75% will vest in equal installments on a quarterly basis over the following 30 months, subject to possible acceleration or forfeiture under the plan terms.
Sharon Simon reported acquisition or exercise transactions in this Form 4 filing.
Microbot Medical Inc. reported that General Manager and CTO Sharon Simon was granted stock options covering 105,000 shares of common stock. According to the company’s 2020 Omnibus Performance Award Plan, 25% of the options vest and become exercisable on August 18, 2026, with the remaining 75% vesting in equal quarterly installments over the following 30 months, subject to the plan’s acceleration or forfeiture provisions.
Vaknin Rachel reported acquisition or exercise transactions in this Form 4 filing.
Microbot Medical Inc. reported that its Chief Financial Officer, Rachel Vaknin, received a grant of stock options covering 105,000 shares of common stock. The award is a right to buy shares under the company’s 2020 Omnibus Performance Award Plan, as amended.
According to the grant terms, 25% of the options will vest and become exercisable on August 18, 2026. The remaining 75% will vest and become exercisable in equal installments on a quarterly basis over the following 30 months, subject to possible acceleration or forfeiture under the plan.
Microbot Medical Inc. filed an 8-K to share that CEO, President and Chairman Harel Gadot will be a featured panelist at The Surgical Disruptive Technology Summit during the SAGES NBT Innovation Weekend in Houston. He will join a session on endovascular therapeutics, AI and robotics.
The company uses this event to spotlight its LIBERTY Endovascular Robotic System, described as the only FDA cleared, single-use, remotely operated robotic system for peripheral endovascular procedures. Microbot began a limited market release of LIBERTY in late 2025 and plans a full market release at the Society of Interventional Radiology conference in April 2026.